Rubraca (rucaparib tablets – pharmaand GmbH) — Cigna
Ovarian, Fallopian Tube, or Primary Peritoneal Cancer – Maintenance Therapy
Initial criteria
- Patient age ≥ 18 years
- Patient is in complete or partial response after a platinum-based chemotherapy regimen
- Patient meets ONE of the following (i or ii): i. Patient meets BOTH of the following (a and b): a) Patient has recurrent disease; AND b) Patient has a BRCA mutation; OR ii. Patient is in complete or partial response to first-line primary treatment
Approval duration
1 year